NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis $7.41 +1.33 (+21.88%) Closing price 08/7/2026 04:00 PM EasternExtended Trading$7.37 -0.04 (-0.54%) As of 08/7/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arcturus Therapeutics Stock (NASDAQ:ARCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arcturus Therapeutics alerts:Sign Up Key Stats Today's Range$6.45▼$7.5650-Day Range$5.53▼$8.0452-Week Range$5.50▼$24.17Volume1.46 million shsAverage Volume494,825 shsMarket Capitalization$210.59 millionP/E RatioN/ADividend YieldN/APrice Target$24.25Consensus RatingModerate Buy Company Overview Arcturus Therapeutics Holdings Inc. is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases. The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore. Additional preclinical programs are directed toward addressing other metabolic disorders and infectious diseases. Arcturus’s research and development efforts focus on leveraging mRNA’s capacity for rapid design and production, aiming to reduce development timelines compared with traditional biologics. Headquartered in San Diego, California, Arcturus maintains research and manufacturing facilities both in the United States and in Singapore, reflecting its commitment to global collaboration and supply chain resilience. The Singapore facility supports the company’s vaccine development programs and provides clinical-scale manufacturing capabilities to meet regulatory requirements in multiple jurisdictions. Since going public in 2018, Arcturus has been led by Chief Executive Officer Joseph E. Payne, who brings experience from several biotechnology and pharmaceutical roles. Under his leadership, the company has forged partnerships with academic institutions and contract manufacturing organizations to advance its clinical programs. Arcturus continues to explore new applications of its mRNA platform through collaborations and licensing agreements aimed at expanding its pipeline and demonstrating the versatility of mRNA-based therapeutics.AI Generated. May Contain Errors. Read More Arcturus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreARCT MarketRank™: Arcturus Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 497th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingArcturus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 1 strong buy rating, 6 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialArcturus Therapeutics has a consensus price target of $24.25, representing about 227.3% upside from its current price of $7.41.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Arcturus Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($3.99) to ($3.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.98% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 10.71, which indicates bearish sentiment.Change versus previous monthShort interest in Arcturus Therapeutics has recently increased by 2.98%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.46 News SentimentArcturus Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Arcturus Therapeutics this week, compared to 5 articles on an average week.Search Interest8 people have searched for ARCT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows1 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARCT Stock News HeadlinesWall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to "Sell"August 9 at 1:12 AM | americanbankingnews.comArcturus targets Q4 2026 Phase III decision for ARCT-032 as it regains global KOSTAIVE rightsAugust 7 at 6:15 PM | seekingalpha.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.August 9 at 1:00 AM | Base Camp Trading (Ad)Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline ProgressAugust 7 at 1:14 PM | finance.yahoo.comArcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call TranscriptAugust 7 at 9:00 AM | seekingalpha.comEarnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Q2 2026 -- GF Value Sees 44% DownsideAugust 5, 2026 | finance.yahoo.comArcturus Therapeutics (NASDAQ:ARCT) Stock Rating Lowered by Wall Street ZenAugust 1, 2026 | americanbankingnews.comArcturus Therapeutics (ARCT) Projected to Release Earnings on ThursdayJuly 31, 2026 | americanbankingnews.comSee More Headlines ARCT Stock Analysis - Frequently Asked Questions How have ARCT shares performed this year? Arcturus Therapeutics' stock was trading at $6.13 at the start of the year. Since then, ARCT stock has increased by 20.9% and is now trading at $7.41. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.16. The biotechnology company had revenue of $2.96 million for the quarter, compared to the consensus estimate of $3.11 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 46.54% and a negative net margin of 317.62%. Read the conference call transcript. Who are Arcturus Therapeutics' major shareholders? Top institutional investors of Arcturus Therapeutics include BlackRock Inc. (9.20%), Hennion & Walsh Asset Management Inc. (1.22%), Bank of New York Mellon Corp (0.28%) and GSA Capital Partners LLP (0.17%). View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings8/06/2026Today8/09/2026Canaccord Genuity's 46th Annual Growth Conference8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 ARCT's financial health is in the Red zone, according to TradeSmith. ARCT has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARCT CIK1768224 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees180Year Founded2013Price Target and Rating Average Price Target for Arcturus Therapeutics$24.25 High Price Target$54.00 Low Price Target$9.00 Potential Upside/Downside+227.3%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.78 million Net Margins-317.62% Pretax Margin-317.64% Return on Equity-46.54% Return on Assets-36.46% Debt Debt-to-Equity RatioN/A Current Ratio5.88 Quick Ratio5.88 Sales & Book Value Annual Sales$82.03 million Price / Sales2.57 Cash FlowN/A Price / Cash FlowN/A Book Value$7.53 per share Price / Book0.98Miscellaneous Outstanding Shares28,420,000Free Float23,364,000Market Cap$210.59 million OptionableOptionable Beta2.39 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ARCT) was last updated on 8/9/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
